5 August 2021PatentsMuireann Bolger

Rejected post-Arthrex bids signal uncertainty over USPTO director’s authority

Early signs show that US v Arthrex is unlikely to herald a spate of inter partes reviews, but may fuel uncertainty around the scope of the acting USPTO director’s role, lawyers have told WIPR.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Patents

Apple and Intel weigh in on SCOTUS Arthrex review

4 December 2020 Apple and Intel, along with tech and IP groups, are urging the US Supreme Court to retain an administrative process for challenging patents.

Patents

Federal Circuit refuses Arthrex rerun, prerogative now with SCOTUS

24 March 2020 The US Court of Appeals for the Federal Circuit will leave it to the Supreme Court to review its controversial Arthrex decision that Patent Trial and Appeal Board judges were unconstitutionally appointed.

Patents

Fed Circ rules on interim USPTO commissioner reviews

20 December 2022 The temporary director’s authority was challenged | Question mark over constitutionality of granted director reviews | SCOTUS.